Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Ovid Therapeutics

08/08/2025 18:42

Ovid Therapeutics Inc OVID.OQ OVID.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The New York City-based  company is expected to report a 54.6% decrease in revenue to $76.67 thousand from $169 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ovid Therapeutics Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.00, about 83% above its last closing price of $0.51

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.14
-0.14
-0.14
Met
-2.4
Dec. 31 2025
-0.17
-0.17
-0.13
Beat
21.7
Sep. 30 2024
-0.19
-0.20
-0.20
Met
1.9​
Jun. 30 2024
-0.20
-0.22
0.12
Beat
154.1
​​Mar. 31 2024
-0.22
-0.22
-0.17
Beat
22
Dec. 31 2023
0.25
-0.05
-0.22
Missed
-342.6​
Sep. 30 2023
-0.19
-0.19
-0.16
Beat
15.2
Jun. 30 2023
-0.20
-0.20
-0.18
Beat
12

This summary was machine generated August 8 at 17:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)